Screener
R&D at other companies
Other financials
Where this comes from
Reported directly by Climb Bio, Inc. in its filing.
Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.
The source filing: Climb Bio, Inc.’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 7:30 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-210357
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Operating expenses: | ||
| Research and development | $9,373 | $17,327 |
| General and administrative | 5,838 | 5,691 |
| Total operating expenses | 15,211 | 23,018 |
| Loss from operations | (15,211) | (23,018) |
| Other income (expense): | ||
| Interest income | 1,514 | 2,287 |
| Foreign currency (loss) | (25) | (50) |
Item 1. Condensed Consolidated Financial Statements (unaudited)
FAQ
- What is Climb Bio, Inc.'s R&D?
- Climb Bio, Inc. (CLYM) reported R&D of $9.37M in Q1 2026.
- How has Climb Bio, Inc.'s R&D changed year-over-year?
- Climb Bio, Inc.'s R&D decreased by 45.9% year-over-year, from $17.33M to $9.37M.
- What is the long-term trend for Climb Bio, Inc.'s R&D?
- Over 4 years (2021 to 2025), Climb Bio, Inc.'s R&D has grown at a 19.9% compound annual growth rate (CAGR), from $22.62M to $46.71M.
- What does R&D mean?
- Costs of research activities to discover new knowledge and development activities to translate research into new or improved products, services, processes, or technologies.
Ask your AI about Climb Bio, Inc.'s r&d.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude